About
Operator-led diligence. Senior judgment on the questions that decide the investment.
Strategic Value Inflections is built around a simple premise: investment questions should be assessed by people who have owned comparable decisions, not just studied them. Every engagement is led by Bob Basore, with senior specialists added only where their specific expertise materially improves the answer.
Why the operating background matters
Bob's experience spans strategy and portfolio management, oncology R&D, corporate development and M&A, alliances, international businesses, commercialization, market access, diagnostics, medical devices, and P&L leadership. That breadth matters because the assumptions in an investment case rarely stay inside one function. A regulatory issue can change timing and capital. A reimbursement issue can change adoption and revenue. A manufacturing constraint can change launch feasibility. An organizational gap can change whether any of those assumptions are executable.
Senior specialists, used selectively
Where an engagement requires additional depth, SVI draws on independent senior operators and practitioners in the relevant discipline, including regulatory, clinical development, reimbursement and market access, health economics, manufacturing, and customer or market research. Specialists contribute defined findings. SVI integrates those findings into the investment decision and remains accountable for the overall conclusion.
IP work remains issue spotting. Formal freedom-to-operate or other legal opinions are referred to qualified counsel.
Improving Investment Decision Quality Through Experience, Insight & Evidence
I started SVI to help investors and leadership teams improve the quality of the decisions that determine value. Over the course of my career, I have worked across nearly every part of the pharmaceutical and medical device value chain, from R&D, sales, marketing, national accounts, and global commercial operations to Strategy & Portfolio Management, oncology drug development, Corporate Development, M&A, and ultimately serving as CEO of a biotechnology company.
I have built and led organizations, licensed technologies, developed therapeutic platforms, advanced oncology assets from early development into the clinic, shaped portfolio and growth strategies, participated in more than $10 billion of M&A, and spent a decade advising pharmaceutical, biotechnology, and medical device companies.
That experience taught me that rigorous diligence cannot stop with the clinical data, market model, or spreadsheet. The quality of the organization, leadership team, development capabilities, operating plan, and resources available to execute are often just as important to an investment outcome. Two companies can hold essentially the same asset and data package yet represent very different risk-adjusted values because their ability to navigate development, regulatory, commercial, financing, and execution risks is different.
SVI was created to bring that operator's perspective to private equity and venture capital diligence, combining experience, insight, and data to identify the risks and opportunities that matter most, pressure-test the assumptions behind the investment case, and help clients make better-informed decisions with greater confidence.
Career background
Former employer names are not disclosed on this site. Roles and accomplishments are described by function and sector.
2016 – present
Managing Director, Strategic Value Inflections
Buy- and sell-side diligence, valuation, and strategic assessment for PE deal teams and life-sciences leadership. Commercial and technical diligence across pharma, biotech, device, and diagnostics. Built analytical tools for operating-cost and loss-of-exclusivity risk assessment.
2021
CEO, early-stage immuno-oncology company
Set corporate vision, R&D and clinical strategy, and regulatory path for a platform spanning oncolytic virus, immunomodulator, and vaccine programs. Led partnerships and capital strategy toward defined clinical milestones.
2005 – 2016
Multiple VP roles, large specialty pharmaceutical company
Eleven years across five VP functions: M&A/BD & Alliances, Oncology R&D/BD/Alliances, Oncology BD & Strategic Alliances, Corporate Strategy & Portfolio Management, and International Marketing. Involvement in $10B+ of acquisitions and divestitures. Built the company's oncology pipeline, led cross-functional teams of 90+, and owned P&L responsibilities up to $1.2B.
2004 – 2005
VP Worldwide Sales & Marketing, point-of-care diagnostics company
Restructured global go-to-market and sales execution. Led diligence readiness and sale negotiations that resulted in a successful acquisition.
2000 – 2003
VP Sales & Marketing (North & Latin America), global diagnostics company
Full P&L for direct and distributor channels across North and Latin America. Rebuilt the commercial model and distributor network; introduced commercial excellence frameworks.
1997 – 2000
National Director, IHNs/GPOs/Distribution, major healthcare diagnostics company
Owned $550M U.S. P&L across integrated health networks, GPOs, and distributors. Created disease-management programs in Diabetes, ESRD, and Anemia generating $100M+ in new revenue through value-based contracting.
$10B+
M&A and BD transactions across executive and advisory roles
VP
Roles across 6 distinct corporate functions
CEO
Early-stage immuno-oncology company
5 sectors
Pharma · Biotech · Device · Diagnostics · Radiopharma
Education & executive development
B.S. Packaging Engineering, Business Emphasis
Michigan State University
Executive Mergers & Acquisitions
Northwestern Kellogg School of Management
Executive Finance
University of Notre Dame
Executive Leadership · Executive Corporate Strategy
Washington University
BD&L, Negotiation, Portfolio Management
LES, BIO, McKinsey, Kellogg, Karrass
Advisory & oversight roles
- Translational Medicine Oversight Committee, academic medical center: business, payer, and R&D guidance to early-stage pharma and device investments
- Cancer Research Center advisory: strategic, R&D, and corporate development guidance for immuno-oncology and biologic assets
- R&D Advisory Board, academic research institution: market and payer guidance on university-stage investments
Geographic base
Based in Ann Arbor, Michigan. Engagements conducted nationally and internationally, drawing on US, EMEA, APAC, and LATAM market experience across prior VP roles.